News | November 10, 2025
Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Relmada expects to initiate its Phase 3 program in the first half of 2026
Venus Remedies now has 29 active product approvals in Vietnam alone
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
Subscribe To Our Newsletter & Stay Updated
